Policy

Govt removes restrictions on export of 12 pharma items

Our Bureau New Delhi | Updated on April 07, 2020 Published on April 07, 2020

DGFT allows export of APIs, formulations including vitamins, antibiotics after producers say they have surplus stocks

The Centre has allowed export of a dozen active pharmaceutical ingredients (API), including antibiotics, vitamins and hormones as well as their formulations, that were placed under restriction early last month to avoid a domestic shortage due to the Covid-19 outbreak.

A notification, amending the one issued on March 3, was put up by the Directorate General of Foreign Trade (DGFT) late Monday night specifying that export of the 12 identified APIs was now free.

These APIs include Tinidazole, Metronidazole, Acyclovir, Vitamin B1, B6, B12, Progesterone, Chloramphenicol, Erythromycin salts, Neomycin, Clindamycin salts and Ornidazole.

“The notification....is amended to the extent that the above-mentioned APIs and formulations made from these are made free for export with immediate effect,” noted the amended notification issued by the DGFT on April 6.

Although US President Donald Trump has requested Prime Minister Narendra Modi to allow export of hydroxychloroquine, an anti-malaria drug being increasingly used to treat Covid-19 in many countries, the government is yet to take a call on this matter.

Following the restriction imposed on exports of several antibiotics, vitamins and hormonal medicines on March 3, a number of drug companies, including pharmaceutical body Indian Pharmaceutical Alliance, had sought the removal of the prohibition on the ground that domestic companies had surplus stocks for export.

Published on April 07, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.